## Results  
### Study Population  
Figure 2 illustrates the participant onboarding procedure. Table 1 summarizes the participant demographic information, further details of which are provided in Appendix C. All the participants were recruited and screened for eligibility from 5 June 2018 through 12 June 2018, when the targeted number of participants was met. At baseline, the experimental (EXP) and control (CON) groups did not display statistically significant differences in the mean age (EXP: \(72.71\pm 9.86\) vs. CON: \(72.67\pm 12.64\) years, \(t(27)=0.03\), \(p=0.98\)), the proportion of males and females (EXP: 0.14 vs. CON: 0.13, \(\chi^{2}(1)=0.00\), \(p=1\)), the proportion of subjects with left and right hemipares (EXP: 0.50 vs. CON: 0.36, \(\chi^{2}(1)=0.15,p=0.70\)), the mean MFT scores for both the affected (EXP: \(14\pm 9.65\) vs. CON: \(15.80\pm 6.60\), \(t(27)=0.59\), \(p=0.56\)) and the unaffected limbs (EXP: \(27.07\pm 2.37\) vs. CON: \(28.33\pm 1.91\), \(t(27)=1.58\), \(p=0.13\)), and the proportion of left and right-handed subjects (EXP: 0.07 vs. CON: 0.00, \(\chi^{2}(1)=0.00,p=0.97\)). However, the mean length of time since the stroke (i.e., chronicity) of the experimental group was significantly greater than that of the control group (EXP: \(74.07\pm 40.84\) vs. CON: \(45.47\pm 19.82\) months, \(t(27)=2.43\), \(p=0.02\)) albeit both being well within the chronic phase. None of the participants were diagnosed with any language disorders (e.g., aphasia), which may introduce challenges in following text and audio instructions and self-administering _Neuro-world_ games. \begin{table}
\begin{tabular}{l l l} \hline \hline
**Baseline Demographic Data for 29 Stroke Survivors** & **Experimental** & **Control** \\ \hline Patients, No. & 14 & 15 \\ \hline Age, mean (standard deviation), y. & 72.71 (9.86) & 72.67 (12.64) \\ \hline Sex, No. (\%) & & \\ Men & 2 (14.29) & 2 (13.33) \\ Women & 12 (85.71) & 13 (86.67) \\ \hline Diagnosis, No. (\%) & & \\ Ischemic stroke & 11 (78.57) & 13 (86.67) \\ Hemorrhagic stroke & 3 (21.43) & 2 (13.33) \\ \hline Chronicity, mean (standard deviation), m. & 74.07 (40.84) & 45.47 (19.82) * \\ \hline Affected Side, No. (\%) & & \\ Left & 7 (50.00) & 5 (35.71) \\ Right & 7 (50.00) & 9 (64.29) \\ \hline Manual Function test, mean (standard deviation) score & & \\ Affected Limb & 14.00 (9.65) & 15.80 (6.60) \\ Undinfected Limb & 27.07 (2.37) & 28.33 (1.91) \\ \hline MMSE, mean (standard deviation) score & & \\ Orientation & 7.93 (1.82) & 8.07 (1.49) \\ Register & 2.57 (0.51) & 2.13 (0.83) \\ Attention and calculation & 2.57 (0.51) & 2.13 (0.83) \\ Recall & 1.21 (0.80) & 0.67 (0.62) \\ Language & 7.71 (0.83) & 7.87 (0.63) \\ Total score & 21.64 (1.08) & 20.87 (1.30) \\ \hline Digit spanning, mean (standard deviation) score & & \\ Forward & 7.36 (2.17) & 6.13 (1.25) \\ Backward & 4.14 (1.29) & 2.93 (0.88) \\ \hline GDS, mean (standard deviation), score & 3.79 (0.43) & 4.00 (0.00) \\ \hline \hline \end{tabular}  
* indicates that the difference is statistically significant (\(p<0.05\)).  
\end{table} 
Table 1: Baseline patient demographic information. Figure 2: Participant Onboarding Procedure. Fifty-six volunteered chronic stroke survivors were screened for eligibility. Six were determined to be ineligible for the study because they scored less than 18 points in the initial MMSE assessment. Fifty participants were randomly assigned to the experimental vs. control groups. During the study, three participants expressed cognitive fatigue during gameplay and withdrew their consent. Ten participants were either discharged or transferred to other medical institutions. Eight participants withdrew their consents due to their health issues (e.g., headache or pain from arthritis), which were not related to the administration of _Neuro-World_. As a result, 14 participants from the experimental group and 15 participants from the control group completed the study.